MustGrow Announces Grant of RSUs and DSUs
MustGrow Biologics (OTCQB: MGROF) announced the grant of 1,660,315 deferred share units (DSUs) and restricted share units (RSUs) to directors, officers, and consultants, effective September 25, 2025. The grants were made under the company's Omnibus Equity Incentive Plan.
The DSUs will vest upon the holder's departure from their role at the company or its affiliates. Upon settlement, DSU holders will receive either one common share or an equivalent cash payment at the company's discretion.
MustGrow Biologics (OTCQB: MGROF) ha annunciato la concessione di 1.660.315 unità differite di azioni (DSU) e unità di azioni vincolate (RSU) a membri del consiglio, dirigenti e consulenti, con effetto dal 25 settembre 2025. Le assegnazioni sono state effettuate ai sensi del piano Omnibus di incentivazione azionaria dell'azienda.
Le DSU saranno acquisite al verificarsi della cessazione del ruolo del titolare presso la società o le sue affiliate. Al momento dell'elaborazione, i detentori delle DSU riceveranno o una singola azione ordinaria o un pagamento in contanti equivalente, a discrezione della società.
MustGrow Biologics (OTCQB: MGROF) anunció la concesión de 1.660.315 unidades diferidas de acciones (DSU) y unidades de acciones restringidas (RSU) a directores, ejecutivos y consultores, con efecto a partir del 25 de septiembre de 2025. Las adjudicaciones se realizaron en virtud del Omnibus Equity Incentive Plan de la empresa.
Las DSU se consolidarán al momento de la salida del titular de su cargo en la empresa o sus filiales. Al vencimiento, los titulares de DSU recibirán ya sea una acción común o un pago en efectivo equivalente, a discreción de la empresa.
MustGrow Biologics (OTCQB: MGROF)가 2025년 9월 25일부로 이사회 구성원, 임원 및 컨설턴트에게 1,660,315 주식지연단위(DSU)와 제한주식단위(RSU)를 부여했다고 발표했습니다. 이 보상은 회사의 Omnibus Equity Incentive Plan에 따라 이루어졌습니다.
DSU는 보유자가 회사 또는 계열사에서 직위를 떠날 때 확정됩니다. 정산 시, DSU 보유자는 회사의 재량에 따라 보통주 1주 또는 해당 현금 지급을 받게 됩니다.
MustGrow Biologics (OTCQB : MGROF) a annoncé l'octroi de 1 660 315 unités d'actions différées (DSU) et d'unités d'actions restreintes (RSU) à des administrateurs, dirigeants et consultants, en vigueur à partir du 25 septembre 2025. Les attributions ont été effectuées en vertu du plan Omnibus d'incitation à l'équité de l'entreprise.
Les DSU se vestent au moment du départ du titulaire de son poste au sein de la société ou de ses affiliés. À l'exercice, les titulaires de DSU recevront soit une action ordinaire, soit un paiement en espèces équivalent, à la discrétion de la société.
MustGrow Biologics (OTCQB: MGROF) gab bekannt, dass 1.660.315 Deferred Share Units (DSUs) und Restricted Share Units (RSUs) an Direktoren, Führungskräfte und Berater vergeben wurden, wirksam ab dem 25. September 2025. Die Zuweisungen erfolgten im Rahmen des Omnibus Equity Incentive Plans des Unternehmens.
Die DSUs verfallen, wenn der Inhaber seine Rolle beim Unternehmen oder dessen Tochtergesellschaften verlässt. Bei Abrechnung erhalten DSU-Inhaber nach Ermessen des Unternehmens entweder eine Stammaktie oder eine entsprechende Barauszahlung.
MustGrow Biologics (OTCQB: MGROF) أعلنت عن منح 1,660,315 وحدة أسهم مؤجلة (DSU) ووحدات أسهم مقيدة (RSU) إلى أعضاء مجلس الإدارة، والمديرين التنفيذيين، والمستشارين، اعتباراً من 25 سبتمبر 2025. تمت المنح بموجب خطة الحوافز الشاملة للأسهم Omnibus Equity Incentive Plan للشركة.
ستُكتسب DSU عند مغادرة حاملها من دوره في الشركة أو الشركات التابعة. عند التسوية، سيحصل حاملو DSU إما على سهم عادي واحد أو دفعة نقدية مكافئة، وفقاً لتقدير الشركة.
MustGrow Biologics (OTCQB: MGROF) 宣布向董事、管理层和顾问授予 1,660,315 份递延股份单位 (DSU) 和受限股份单位 (RSU)，自 2025 年 9 月 25 日起生效。该授予基于公司的 Omnibus Equity Incentive Plan。
DSU 将在持有人离开其在公司或其关联公司中的职位时兑现。结算时，DSU 持有者将按公司自行决定，获得一股普通股或等值现金支付。
- None.
- None.
Saskatoon, Saskatchewan--(Newsfile Corp. - September 26, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") today announced that the board of directors of the Company authorized and approved the grant of a total of 1,660,315 deferred share units ("DSUs") and restricted share units ("RSUs") to certain directors, officers, and consultants of the Company, effective September 25, 2025. This grants of DSUs and RSUs are made pursuant to the Company's Omnibus Equity Incentive Plan (the "Plan").
The DSUs will vest when the holder ceases to be a director, officer or employee of the Company or any of its affiliates, as applicable. On settlement, each DSU will entitle the holder to recive to receive one common share in the capital of the Company or a cash payment equivalent thereof at the discretion of the Company.
---------
About MustGrow
MustGrow Biologics Corp. is a fully-integrated provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company's proprietary and third-party product lines offer eco-friendly alternatives to restricted or banned synthetic chemicals and fertilizers. In North America, MustGrow offers a portfolio of third-party crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, adjuvants and foliar products. These products are synergistically distributed alongside MustGrow's wholly-owned proprietary products and technologies that are derived from mustard and developed into organic biocontrol and biofertility products to help replace banned or restricted synthetic chemicals and fertilizers. Outside of North America, MustGrow is focused on collaborating with agriculture companies, such as Bayer AG in Europe, the Middle East and Africa, to commercialize MustGrow's wholly-owned proprietary products and technologies. The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio of approximately 109 patents that are currently issued and pending, and the sales and distribution of its proprietary and third-party product lines through NexusBioAg. MustGrow is a publicly traded company (TSXV: MGRO) and has approximately 58.9 million common shares issued and outstanding and 69.1 million shares fully diluted. For further details, please visit www.mustgrow.ca.
Contact Information
Corey Giasson
Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca
This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.
Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.
© 2024 MustGrow Biologics Corp. All rights reserved.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/268059
FAQ
How many DSUs and RSUs did MustGrow Biologics (MGROF) grant in September 2025?
When do the MustGrow Biologics DSUs vest?
What will DSU holders receive upon settlement at MustGrow Biologics?
Under which plan were the MustGrow Biologics DSUs and RSUs granted?
